Completed NA INTERVENTIONAL 2-arm NCT07063706

Pharmaceutical Care for Patients Using Capecitabine

Impact of Pharmaceutical Care on Patients Using Capecitabine: a Multicenter Randomized Clinical Trial

Sponsor: Faculdade de Farmácia

Conditions Adverse Drug Reaction (ADR) Cancer Colorectal Cancer Gi Capecitabine Pharmaceutical Services

Updated 2 times since 2025 Last updated: Jul 15, 2025 Started: Mar 1, 2022 Primary completion: Mar 31, 2024 Completion: Aug 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07063706, this NA trial focuses on Adverse Drug Reaction (ADR) and Cancer Colorectal and remains completed. Sponsored by Faculdade de Farmácia, it has been updated 2 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Aug 2025 — Sep 2025 [monthly]

Completed NA

First recorded

Mar 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Faculdade de Farmácia
Instituto Nacional de Cancer, Brazil
Universidade Federal Fluminense
Universidade Federal do Rio de Janeiro

Data source: Faculdade de Farmácia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rio de Janeiro, Brazil